工程化可控 CAR-T 细胞疗法：从二元安全开关到可编程免疫

Engineering controllable CAR T-cell therapies: from binary safety switches to programmable immunity.

基因阻断 PD-1/PD-L1 作为肿瘤免疫检查点阻断的替代手段：综述

Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review.

通过靶向 TFF3 重编程肿瘤微环境：增强实体瘤 CAR-T 细胞治疗的潜在新途径

Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。

通往体内 CAR-T 成功之路：有前景的病毒载体与非病毒载体比较

On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors.

CAR-T 细胞疗法中的 TCR：用进废退？

The TCR in CAR T cell therapy: use it or lose it?

面向新兴过继性细胞治疗的基于 PCR 的细胞动力学与生物分布分析展望

Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.

CAR-T 细胞治疗在儿童、青少年和年轻成人癌症患者中的关键作用

The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

基于 CAR 的细胞与基因治疗：来自 ClinicalTrials.gov 的全球临床格局与新兴治疗策略

CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.

血液病、实体瘤和免疫性疾病中造血细胞移植与 CAR-T 的适应证：2025 EBMT 实践推荐

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice reco